Antisense Compounds Targeting Genes Associated with Cystic Fibrosis
OwnerMichelle L. HASTINGS, Wren E. MICHAELSinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing and/or expression of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.
Claims34
A composition comprising one or more modified oligonucleotides, wherein each of the one or more modified oligonucleotides consists of 8 to 30 linked nucleosides, wherein the nucleobase sequence of each of the one or more modified oligonucleotides is at least 80% complementary to an equal-length portion of a target region of a cystic fibrosis transmembrane conductance regulator (CFTR) transcript, wherein the target region is within:
- (a) nucleobase 198,888 and nucleobase 199,094 of SEQ ID NO:
- 130;
- (b) nucleobase 199,705 and nucleobase 199,796 of SEQ ID NO:
- 130.
Dependencies are inferred from the claim text.